Martha Arellano, MD

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (220 ratings)

Role

Hematology Oncology
Specialty

Leukemia Myelodysplastic Syndromes
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2006

Request Appointment

Background

Martha L. Arellano, MD, specializes in the treatment of leukemia and myelodysplastic syndromes. Dr. Arellano started practicing with Emory Healthcare in 2006.
Dr. Arellano is a clinical member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. She currently leads the Department of Hematology and Medical Oncology's Fellowship program.
Dr. Arellano earned her medical degree and subsequent medical trianing from Emory University School of Medicine in Atlanta, Georgia.

Dr. Arellano has been featured in "Best Doctors of America", and has received teaching awards from both fellows and internal medicine residents. She is very active in the community, partnering with organizations such as Leukemia and Lymphoma Society, MDS Foundation, and Aplastic Anemia/MDS International Foundation to educate and provide resources for patients, care takers, and healthcare providers. She is a clinical investigator with a focus on finding treatments and cures for patients with leukemias and myelodysplasitc syndromes.

See Dr. Arellano's publications here.

Titles & Roles

Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Director, Hematology and Medical Oncology Fellowship Program

Emory University School of Medicine
Associate Director, Division of Hematology, Department of Hematology and Medical Oncology

Emory University School of Medicine

Education & Training

Education

Fellowship, Hematology & Oncology, 2006
Emory University School of Medicine
Residency, Internal Medicine, 2003
Emory University School of Medicine
Internship, Internal Medicine, 2001
Emory University School of Medicine
Medical Education, , 2000
Emory University School of Medicine

Board Certifications

Hematology
American Board of Internal Medicine, 2007

Professional Memberships

American Medical Association
American Society of Hematology
American Society of Clinical Oncology
Medical Association of Georgia

View Current Clinical Trials


First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Phase I/II Conditions Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia Location Winship Cancer Institute
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) Phase I/II Conditions Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Location Winship Cancer Institute
A Study of SNDX-5613 in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation Phase I/II Conditions Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage Location Winship Cancer Institute
Extended Access of Momelotinib in Adults With Myelofibrosis Phase Expanded Access Conditions Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Location Winship Cancer Institute

Grants

View Grants

Grant Number	Title
7R01CA174786-07	Oxidative pentose phosphate pathway regulates AMPK homeostasis by balancing opposing LKB1 and PP2A

Title/Journal	Authors	Publication Date
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study. Targeted oncology	M Maris, G Salles, WS Kim, TM Kim, RM Lyons, M Arellano, R Karmali, G Schiller, E Cull, CN Abboud, C Batlevi, I Kagiampakis, MC Rebelatto, Y Lee, LC Kirby, F Wang, J Bothos, DM Townsley, AT Fathi, V Ribrag	29/04/2024
Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood advances	CD DiNardo, GJ Roboz, JM Watts, YF Madanat, GT Prince, P Baratam, S de Botton, AS Stein, JM Foran, ML Arellano, DA Sallman, M Hossain, DM Marchione, X Bai, PA Patel, SM Kapsalis, G Garcia-Manero, AT Fathi	19/04/2024
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer	VH Duong, AS Ruppert, AS Mims, U Borate, EM Stein, MR Baer, W Stock, T Kovacsovics, W Blum, ML Arellano, GJ Schiller, RL Olin, JM Foran, MR Litzow, TL Lin, PA Patel, MC Foster, RL Redner, Z Al-Mansour, CR Cogle, RT Swords, RH Collins, JA Vergilio, NA Heerema, L Rosenberg, AO Yocum, S Marcus, T Chen, F Druggan, M Stefanos, TJ Gana, AB Shoben, BJ Druker, A Burd, JC Byrd, RL Levine, MM Boyiadzis	01/08/2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Journal for immunotherapy of cancer	BD Shah, RD Cassaday, JH Park, R Houot, OO Oluwole, AC Logan, N Boissel, T Leguay, MR Bishop, MS Topp, D Tzachanis, KM O'Dwyer, ML Arellano, Y Lin, MR Baer, GJ Schiller, M Subklewe, M Abedi, MC Minnema, WG Wierda, DJ DeAngelo, PJ Stiff, D Jeyakumar, D Mao, S Adhikary, L Zhou, PC Schuberth, R Damico Khalid, A Ghobadia	01/08/2023
Passenger pathogens on physicians. American journal of infection control	CR Funk, S Ravindranathan, A Matelski, H Zhang, C Taylor, S Chandrasekaran, M Arellano, AA Langston, N Joseph, EK Waller	01/07/2023
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood advances	AN Saliba, SH Kaufmann, EM Stein, PA Patel, MR Baer, W Stock, M Deininger, W Blum, GJ Schiller, RL Olin, MR Litzow, TL Lin, BJ Ball, MM Boyiadzis, E Traer, O Odenike, ML Arellano, A Walker, VH Duong, T Kovacsovics, RH Collins, AB Shoben, NA Heerema, MC Foster, KL Peterson, PA Schneider, M Martycz, TJ Gana, L Rosenberg, S Marcus, AO Yocum, T Chen, M Stefanos, AS Mims, U Borate, A Burd, BJ Druker, RL Levine, JC Byrd, JM Foran	13/06/2023
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature	GC Issa, I Aldoss, J DiPersio, B Cuglievan, R Stone, M Arellano, MJ Thirman, MR Patel, DS Dickens, S Shenoy, N Shukla, H Kantarjian, SA Armstrong, F Perner, JA Perry, G Rosen, RG Bagley, ML Meyers, P Ordentlich, Y Gu, V Kumar, S Smith, GM McGeehan, EM Stein	01/03/2023
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. Journal of hematology & oncology	BD Shah, A Ghobadi, OO Oluwole, AC Logan, N Boissel, RD Cassaday, T Leguay, MR Bishop, MS Topp, D Tzachanis, KM O'Dwyer, ML Arellano, Y Lin, MR Baer, GJ Schiller, JH Park, M Subklewe, M Abedi, MC Minnema, WG Wierda, DJ DeAngelo, P Stiff, D Jeyakumar, J Dong, S Adhikary, L Zhou, PC Schuberth, I Faghmous, BK Masouleh, R Houot	10/12/2022
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research	DA Pollyea, CD DiNardo, ML Arellano, A Pigneux, W Fiedler, M Konopleva, DA Rizzieri, BD Smith, A Shinagawa, RM Lemoli, M Dail, Y Duan, B Chyla, J Potluri, CL Miller, HM Kantarjian	01/07/2022
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer	HM Kantarjian, KH Begna, JK Altman, SL Goldberg, MA Sekeres, SA Strickland, ML Arellano, DF Claxton, MR Baer, M Gautier, E Berman, K Seiter, SR Solomon, GJ Schiller, SM Luger, A Butrym, G Gaidano, XG Thomas, P Montesinos, DA Rizzieri, DP Quick, P Venugopal, R Gaur, LJ Maness, TM Kadia, F Ravandi, ME Buyse, JH Chiao	01/12/2021
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Molecular cell	D Chen, S Xia, R Zhang, Y Li, CA Famulare, H Fan, R Wu, M Wang, AC Zhu, SE Elf, R Su, L Dong, M Arellano, WG Blum, H Mao, S Lonial, W Stock, O Odenike, M Le Beau, TJ Boggon, C He, J Chen, X Gao, RL Levine, J Chen	16/09/2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet (London, England)	BD Shah, A Ghobadi, OO Oluwole, AC Logan, N Boissel, RD Cassaday, T Leguay, MR Bishop, MS Topp, D Tzachanis, KM O'Dwyer, ML Arellano, Y Lin, MR Baer, GJ Schiller, JH Park, M Subklewe, M Abedi, MC Minnema, WG Wierda, DJ DeAngelo, P Stiff, D Jeyakumar, C Feng, J Dong, T Shen, F Milletti, JM Rossi, R Vezan, BK Masouleh, R Houot	07/08/2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood	BD Shah, MR Bishop, OO Oluwole, AC Logan, MR Baer, WB Donnellan, KM O'Dwyer, H Holmes, ML Arellano, A Ghobadi, JM Pagel, Y Lin, RD Cassaday, JH Park, M Abedi, JE Castro, DJ DeAngelo, AK Malone, R Mawad, GJ Schiller, JM Rossi, A Bot, T Shen, L Goyal, RK Jain, R Vezan, WG Wierda	08/07/2021
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. JCO oncology practice	AP Jillella, ML Arellano, M Gaddh, AA Langston, LT Heffner, EF Winton, ML McLemore, C Zhang, CR Caprara, KS Simon, SL Bolds, S DeBragga, P Karkhanis, SH Krishnamurthy, J Tongol, MM El Geneidy, A Pati, JM Gerber, MR Grunwald, J Cortes, A Bashey, RK Stuart, VK Kota	01/04/2021
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood	GL Uy, I Aldoss, MC Foster, PH Sayre, MJ Wieduwilt, AS Advani, JE Godwin, ML Arellano, KL Sweet, A Emadi, F Ravandi, HP Erba, M Byrne, L Michaelis, MS Topp, N Vey, F Ciceri, MG Carrabba, S Paolini, GA Huls, M Jongen-Lavrencic, M Wermke, P Chevallier, E Gyan, C Récher, PJ Stiff, KM Pettit, B Löwenberg, SE Church, E Anderson, J Vadakekolathu, M Santaguida, MP Rettig, J Muth, T Curtis, E Fehr, K Guo, J Zhao, O Bakkacha, K Jacobs, K Tran, P Kaminker, M Kostova, E Bonvini, RB Walter, JK Davidson-Moncada, S Rutella, JF DiPersio	11/02/2021
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. American journal of hematology	DA Pollyea, K Pratz, A Letai, BA Jonas, AH Wei, V Pullarkat, M Konopleva, MJ Thirman, M Arellano, PS Becker, B Chyla, WJ Hong, Q Jiang, J Potluri, CD DiNardo	01/02/2021
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nature medicine	A Burd, RL Levine, AS Ruppert, AS Mims, U Borate, EM Stein, P Patel, MR Baer, W Stock, M Deininger, W Blum, G Schiller, R Olin, M Litzow, J Foran, TL Lin, B Ball, M Boyiadzis, E Traer, O Odenike, M Arellano, A Walker, VH Duong, T Kovacsovics, R Collins, AB Shoben, NA Heerema, MC Foster, JA Vergilio, T Brennan, C Vietz, E Severson, M Miller, L Rosenberg, S Marcus, A Yocum, T Chen, M Stefanos, B Druker, JC Byrd	01/12/2020
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood advances	J Vadakekolathu, C Lai, S Reeder, SE Church, T Hood, A Lourdusamy, MP Rettig, I Aldoss, AS Advani, J Godwin, MJ Wieduwilt, M Arellano, J Muth, TO Yau, F Ravandi, K Sweet, H Altmann, GA Foulds, F Stölzel, JM Middeke, M Ciciarello, A Curti, PJM Valk, B Löwenberg, I Gojo, M Bornhäuser, JF DiPersio, JK Davidson-Moncada, S Rutella	27/10/2020
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors. Journal of clinical medicine	JH Kong, EF Winton, LT Heffner, M Gaddh, B Hill, J Neely, A Hatcher, M Joseph, M Arellano, F El-Rassi, A Kim, JH Khoury, VK Kota	20/05/2020
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood advances	CJ Lee, S Kim, HR Tecca, S Bo-Subait, R Phelan, R Brazauskas, D Buchbinder, BK Hamilton, M Battiwalla, NS Majhail, HM Lazarus, PJ Shaw, DI Marks, MR Litzow, S Chhabra, Y Inamoto, Z DeFilipp, GC Hildebrandt, RF Olsson, KA Kasow, JL Liesveld, SJ Rotz, SM Badawy, NS Bhatt, JA Yared, KM Page, ML Arellano, M Kent, N Farhadfar, S Seo, P Hematti, CO Freytes, A Rovó, S Ganguly, S Nathan, L Burns, BE Shaw, LS Muffly	24/03/2020
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood	GJ Roboz, CD DiNardo, EM Stein, S de Botton, AS Mims, GT Prince, JK Altman, ML Arellano, W Donnellan, HP Erba, GN Mannis, DA Pollyea, AS Stein, GL Uy, JM Watts, AT Fathi, HM Kantarjian, MS Tallman, S Choe, D Dai, B Fan, H Wang, V Zhang, KE Yen, SM Kapsalis, D Hickman, H Liu, SV Agresta, B Wu, EC Attar, RM Stone	13/02/2020
ERRATUM: Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation. Hematology reports	AP Jillella, ML Arellano, LT Heffner, M Gaddh, AA Langston, HJ Khoury, A Mangaonkar, VK Kota	29/11/2019
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. Cancer discovery	D Chen, S Xia, M Wang, R Lin, Y Li, H Mao, M Aguiar, CA Famulare, AH Shih, CW Brennan, X Gao, Y Pan, S Liu, J Fan, L Jin, L Song, A Zhou, J Mukherjee, RO Pieper, A Mishra, J Peng, M Arellano, WG Blum, S Lonial, TJ Boggon, RL Levine, J Chen	01/06/2019
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood advances	G Garcia-Manero, Y Abaza, K Takahashi, BC Medeiros, M Arellano, SK Khaled, M Patnaik, O Odenike, H Sayar, M Tummala, P Patel, L Maness-Harris, R Stuart, E Traer, K Karamlou, A Yacoub, R Ghalie, R Giorgino, E Atallah	26/02/2019
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood	CD DiNardo, K Pratz, V Pullarkat, BA Jonas, M Arellano, PS Becker, O Frankfurt, M Konopleva, AH Wei, HM Kantarjian, T Xu, WJ Hong, B Chyla, J Potluri, DA Pollyea, A Letai	03/01/2019
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. American journal of hematology	JE Cortes, B Douglas Smith, ES Wang, A Merchant, VG Oehler, M Arellano, DJ DeAngelo, DA Pollyea, MA Sekeres, T Robak, WW Ma, M Zeremski, M Naveed Shaik, A Douglas Laird, A O'Connell, G Chan, MA Schroeder	01/11/2018
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone marrow transplantation	HJ Khoury, AA Langston, VK Kota, JA Wilkinson, I Pusic, A Jillella, S Bauer, AS Kim, D Roberts, Z Al-Kadhimi, I Bodo, E Winton, M Arellano, JF DiPersio	01/07/2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England journal of medicine	CD DiNardo, EM Stein, S de Botton, GJ Roboz, JK Altman, AS Mims, R Swords, RH Collins, GN Mannis, DA Pollyea, W Donnellan, AT Fathi, A Pigneux, HP Erba, GT Prince, AS Stein, GL Uy, JM Foran, E Traer, RK Stuart, ML Arellano, JL Slack, MA Sekeres, C Willekens, S Choe, H Wang, V Zhang, KE Yen, SM Kapsalis, H Yang, D Dai, B Fan, M Goldwasser, H Liu, S Agresta, B Wu, EC Attar, MS Tallman, RM Stone, HM Kantarjian	21/06/2018
How I treat older patients with acute myeloid leukemia. Cancer	M Arellano, JW Carlisle	15/06/2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet. Oncology	CD DiNardo, KW Pratz, A Letai, BA Jonas, AH Wei, M Thirman, M Arellano, MG Frattini, H Kantarjian, R Popovic, B Chyla, T Xu, M Dunbar, SK Agarwal, R Humerickhouse, M Mabry, J Potluri, M Konopleva, DA Pollyea	01/02/2018
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib. Clinical lymphoma, myeloma & leukemia	VK Kota, JH Kong, M Arellano, F El Rassi, M Gaddh, LT Heffner, EF Winton, AP Jillella, ML McLemore, HJ Khoury	01/12/2017
Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation. Hematology reports	AP Jillella, ML Arellano, LT Heffner, M Gaddh, AA Langston, HJ Khoury, A Mangoankar, VK Kota	26/09/2017
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia? Cancer	JH Kong, EF Winton, LT Heffner, Z Chen, AA Langston, B Hill, M Arellano, F El-Rassi, A Kim, A Jillella, VK Kota, I Bodó, HJ Khoury	01/07/2017
Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin. Oncogene	S Elf, R Lin, S Xia, Y Pan, C Shan, S Wu, S Lonial, M Gaddh, ML Arellano, HJ Khoury, FR Khuri, BH Lee, TJ Boggon, J Fan, J Chen	12/01/2017
Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. Molecular cell	J Fan, R Lin, S Xia, D Chen, SE Elf, S Liu, Y Pan, H Xu, Z Qian, M Wang, C Shan, L Zhou, QY Lei, Y Li, H Mao, BH Lee, J Sudderth, RJ DeBerardinis, G Zhang, T Owonikoko, M Gaddh, ML Arellano, HJ Khoury, FR Khuri, S Kang, PW Doetsch, S Lonial, TJ Boggon, WJ Curran, J Chen	01/12/2016
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia? Clinical lymphoma, myeloma & leukemia	Z DeFilipp, AA Langston, Z Chen, C Zhang, ML Arellano, F El Rassi, CR Flowers, VK Kota, Z Al-Kadhimi, R Veldman, AP Jillella, S Lonial, EK Waller, HJ Khoury	01/08/2016
Clinical significance of quantitative monitoring and mutational analysis of BCR-ABL1 transcript in Philadelphia chromosome positive B lymphoblastic leukemia. Leukemia & lymphoma	L Zhang, RT Ramjit, CE Hill, M Arellano, HJ Khoury, KP Mann	01/02/2016
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nature cell biology	R Lin, S Elf, C Shan, HB Kang, Q Ji, L Zhou, T Hitosugi, L Zhang, S Zhang, JH Seo, J Xie, M Tucker, TL Gu, J Sudderth, L Jiang, M Mitsche, RJ DeBerardinis, S Wu, Y Li, H Mao, PR Chen, D Wang, GZ Chen, SJ Hurwitz, S Lonial, ML Arellano, HJ Khoury, FR Khuri, BH Lee, Q Lei, DJ Brat, K Ye, TJ Boggon, C He, S Kang, J Fan, J Chen	01/11/2015
Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process. Current treatment options in oncology	SB Zeichner, ML Arellano	01/08/2015
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Investigational new drugs	G Garcia-Manero, R Tibes, T Kadia, H Kantarjian, M Arellano, EA Knight, H Xiong, Q Qin, W Munasinghe, L Roberts-Rapp, P Ansell, DH Albert, B Oliver, MD McKee, JL Ricker, HJ Khoury	01/08/2015
Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link? Cancer	F El Rassi, JD Bergsagel, M Arellano, M Gaddh, A Jillella, V Kota, LT Heffner, EF Winton, HJ Khoury	15/03/2015
Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer cell	L Jin, D Li, GN Alesi, J Fan, HB Kang, Z Lu, TJ Boggon, P Jin, H Yi, ER Wright, D Duong, NT Seyfried, R Egnatchik, RJ DeBerardinis, KR Magliocca, C He, ML Arellano, HJ Khoury, DM Shin, FR Khuri, S Kang	09/02/2015
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome. Leukemia & lymphoma	GJ Roboz, HJ Khoury, E Jabbour, W Session, EK Ritchie, H Miao, S Faderl, W Zheng, EJ Feldman, M Arellano, JG Morrison, F Ravandi	01/02/2015
A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia. Clinical lymphoma, myeloma & leukemia	ML Arellano, G Borthakur, M Berger, J Luer, A Raza	01/12/2014
Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect. The Journal of biological chemistry	J Fan, HB Kang, C Shan, S Elf, R Lin, J Xie, TL Gu, M Aguiar, S Lonning, TW Chung, M Arellano, HJ Khoury, DM Shin, FR Khuri, TJ Boggon, S Kang, J Chen	19/09/2014
Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. Molecular cell	C Shan, S Elf, Q Ji, HB Kang, L Zhou, T Hitosugi, L Jin, R Lin, L Zhang, JH Seo, J Xie, M Tucker, TL Gu, J Sudderth, L Jiang, RJ DeBerardinis, S Wu, Y Li, H Mao, PR Chen, D Wang, GZ Chen, S Lonial, ML Arellano, HJ Khoury, FR Khuri, BH Lee, DJ Brat, K Ye, TJ Boggon, C He, S Kang, J Fan, J Chen	21/08/2014
Incidence and geographic distribution of adult acute leukemia in the state of Georgia. Southern medical journal	F El Rassi, KC Ward, CR Flowers, LT Heffner, EK Waller, EF Winton, J Vaughn, BG Hill, A Langston, A Nooka, M Arellano, HJ Khoury	01/08/2014
Tyr-94 phosphorylation inhibits pyruvate dehydrogenase phosphatase 1 and promotes tumor growth. The Journal of biological chemistry	C Shan, HB Kang, S Elf, J Xie, TL Gu, M Aguiar, S Lonning, T Hitosugi, TW Chung, M Arellano, HJ Khoury, DM Shin, FR Khuri, TJ Boggon, J Fan	01/08/2014
Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma	Z Mitri, MT Siddiqui, F El Rassi, JT Holden, LT Heffner, A Langston, EK Waller, E Winton, M McLemore, L Bernal-Mizrachi, D Jaye, M Arellano, HJ Khoury	01/07/2014
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	GJ Roboz, T Rosenblat, M Arellano, M Gobbi, JK Altman, P Montesinos, C O'Connell, SR Solomon, A Pigneux, N Vey, R Hills, TF Jacobsen, A Gianella-Borradori, Ø Foss, S Vetrhusand, FJ Giles	20/06/2014
Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia	V Bachanova, DI Marks, MJ Zhang, H Wang, M de Lima, MD Aljurf, M Arellano, AS Artz, U Bacher, JY Cahn, YB Chen, EA Copelan, WR Drobyski, RP Gale, JP Greer, V Gupta, GA Hale, P Kebriaei, HM Lazarus, ID Lewis, VA Lewis, JL Liesveld, MR Litzow, AW Loren, AM Miller, M Norkin, B Oran, J Pidala, JM Rowe, BN Savani, W Saber, R Vij, EK Waller, PH Wiernik, DJ Weisdorf	01/03/2014
Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Molecular cell	J Fan, C Shan, HB Kang, S Elf, J Xie, M Tucker, TL Gu, M Aguiar, S Lonning, H Chen, M Mohammadi, LM Britton, BA Garcia, M Alečković, Y Kang, S Kaluz, N Devi, EG Van Meir, T Hitosugi, JH Seo, S Lonial, M Gaddh, M Arellano, HJ Khoury, FR Khuri, TJ Boggon, S Kang, J Chen	20/02/2014
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma. Clinical lymphoma, myeloma & leukemia	R Sinha, PJ Shenoy, N King, MJ Lechowicz, K Bumpers, D Hutcherson, M Arellano, A Langston, J Kaufman, LT Heffner, EK Waller, A Nooka, CR Flowers, S Lonial	01/12/2013
Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer	AG Antun, S Gleason, M Arellano, AA Langston, ML McLemore, M Gaddh, F el Rassi, L Bernal-Mizrachi, J Galipeau, LT Heffner, EF Winton, HJ Khoury	01/11/2013
Update on optimal management of acute myeloid leukemia. Clinical Medicine Insights. Oncology	F El Rassi, M Arellano	01/01/2013
Tools to optimize the functionality of a leukemia clinical trial team. Leukemia & lymphoma	B Bethelmie-Bryan, K Lord, S Holloway, F Safavi, M Shepard, S Rogers, RD Harvey, K Rodger, EK Waller, B El-Rayes, M Arellano, HJ Khoury	01/01/2013
Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nature communications	T Hitosugi, L Zhou, J Fan, S Elf, L Zhang, J Xie, Y Wang, TL Gu, M Alečković, G LeRoy, Y Kang, HB Kang, JH Seo, C Shan, P Jin, W Gong, S Lonial, ML Arellano, HJ Khoury, GZ Chen, DM Shin, FR Khuri, TJ Boggon, S Kang, C He, J Chen	01/01/2013
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer cell	T Hitosugi, L Zhou, S Elf, J Fan, HB Kang, JH Seo, C Shan, Q Dai, L Zhang, J Xie, TL Gu, P Jin, M Alečković, G LeRoy, Y Kang, JA Sudderth, RJ DeBerardinis, CH Luan, GZ Chen, S Muller, DM Shin, TK Owonikoko, S Lonial, ML Arellano, HJ Khoury, FR Khuri, BH Lee, K Ye, TJ Boggon, S Kang, C He, J Chen	13/11/2012
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. Cancer	M Arellano, S Pakkala, A Langston, M Tighiouart, L Pan, Z Chen, LT Heffner, S Lonial, E Winton, HJ Khoury	01/11/2012
Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis? Chest	A Zhou, A Winkler, A Emamifar, B Gartland, A Duncan, A Antun, M Arellano, GA Tindol, JH Levy, WA Bornstein, IR Horowitz, HJ Khoury	01/11/2012
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. British journal of haematology	D Muringampurath-John, DL Jaye, CR Flowers, D Saxe, Z Chen, MJ Lechowicz, DD Weisenburger, M Bast, ML Arellano, L Bernal-Mizrachi, LT Heffner, M McLemore, JL Kaufman, EF Winton, S Lonial, JO Armitage, HJ Khoury	01/09/2012
A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer	HJ Khoury, G Garcia-Manero, G Borthakur, T Kadia, MC Foudray, M Arellano, A Langston, B Bethelmie-Bryan, S Rush, K Litwiler, S Karan, H Simmons, AI Marcus, M Ptaszynski, H Kantarjian	15/07/2012
Managing chronic myeloid leukemia: a coordinated team care perspective. Clinical lymphoma, myeloma & leukemia	S Holloway, K Lord, B Bethelmie-Bryan, MW Shepard, J Neely, M McLemore, SK Reddy, A Montero, WS Jonas, SP Gladney, SL Khanwani, SC Reddy, AK Lahiry, LT Heffner, E Winton, M Arellano, HJ Khoury	01/04/2012
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Leukemia & lymphoma	D Muringampurath-John, CR Flowers, M Toscano, C Zhengjia, JL Kaufman, M Arellano, L Bernal-Mizrachi, LT Heffner, MJ Lechowicz, M McLemore, E Winton, DL Jaye, S Lonial, HJ Khoury	01/04/2012
High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years. Cancer	M Arellano, E Winton, L Pan, L Lima, M Tighiouart, K Bhalla, LT Heffner, J Neely, D Hutcherson, M McLemore, A Langston, HJ Khoury	15/01/2012
Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia. Clinical lymphoma, myeloma & leukemia	M Arellano, L Bernal-Mizrachi, L Pan, M Tighiouart, L Souza, X Guo, M McLemore, L Lima, S Sunay, LT Heffner, Z Chen, GZ Chen, A Langston, E Winton, HJ Khoury	01/10/2011
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia? Leukemia & lymphoma	LM Lima, K Sampat, S Assouline, D Saxe, S Nault, M Tighiouart, M McLemore, M Arellano, E Winton, L Bernal-Mizrachi, J Cortes, HJ Khoury	01/06/2011
Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer	L Lima, L Bernal-Mizrachi, D Saxe, KP Mann, M Tighiouart, M Arellano, L Heffner, M McLemore, A Langston, E Winton, HJ Khoury	15/03/2011
Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters. Leukemia & lymphoma	H Tran, M Arellano, A Chamsuddin, C Flowers, LT Heffner, A Langston, MJ Lechowicz, A Tindol, E Waller, EF Winton, HJ Khoury	01/08/2010
Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia. Journal of blood medicine	LM Lima, M Arellano, S Holloway, M Shepard, S McMillan, HJ Khoury	01/01/2010
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). Journal of immunotherapy (Hagerstown, Md. : 1997)	M Akhtari, EK Waller, DL Jaye, DH Lawson, R Ibrahim, NE Papadopoulos, ML Arellano	01/04/2009
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. Bone marrow transplantation	S Murali, E Winton, EK Waller, LT Heffner, S Lonial, C Flowers, J Kaufman, M Arellano, MJ Lechowicz, KP Mann, HJ Khoury, AA Langston	01/10/2008
Regulation of alloimmune responses by dendritic cell subsets. Experimental hematology	S Lonial, C Torre, E David, W Harris, M Arellano, EK Waller	01/10/2008
Clinical uses of GM-CSF, a critical appraisal and update. Biologics : targets & therapy	M Arellano, S Lonial	01/03/2008
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. Leukemia & lymphoma	S Lonial, M Arellano, D Hutcherson, A Langston, C Flowers, LT Heffner, E Winton, M Jo Lechowicz, EK Waller	01/10/2006

Awards

American Sociaty of Clinical Oncology Young Investigator Award 2006
Best Doctors in America 2011-2015
James R. Eckamn Teaching Award 2018

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.8	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	05/04/2024	Good experience
One star One star One star One star One star	04/04/2024	Thank you Dr. Arellano!
One star One star One star One star One star	02/04/2024	The way she involves in the care planning and provides we will summary notes in my chart
One star One star One star One star One star	08/03/2024	Dr. Arellano is a very professional and caring person. I am very confident under her care.
One star One star One star One star One star	07/03/2024	My doctor was very good. She welcomed me, listened to me closely, asked me questions, described what her plan of action was and reassured me that she will find some answers that have been needed for some time. She also told me we would have a follow up appointment as soon as test and labs are completed.
One star One star One star One star One star	27/02/2024	Today I'm being added for an experimental trial treatment, the first time since starting treatment in 5/15. I am happy!
One star One star One star One star One star	25/01/2024	Good
One star One star One star One star One star	23/01/2024	Excellent communication skils.
One star One star One star One star One star	07/12/2023	Dr. Arellano saved my life.
One star One star One star One star One star	17/10/2023	Good
One star One star One star One star One star	06/10/2023	Dr was very informative and attentive.
One star One star One star One star One star	03/10/2023	Excellent communication skills.
One star One star One star One star One star	08/09/2023	Dr. Arellano is very professional, caring and good communicator. I could not ask for a better Dr.
One star One star One star One star One star	07/09/2023	Dr. Arellano has been a blessing to me since my first appointment with her nearly two years ago. Aplastic Anemia is something that I live with and Dr. Arellano has made me relaxed and less anxious about my condition. I'm very fortunate to have her as my Hematologist!
One star One star One star One star One star	29/08/2023	Dr. Martha Arellano is an excellent doctor and care provider.
One star One star One star One star One star	26/08/2023	Good
One star One star One star One star One star	07/08/2023	Excellent
One star One star One star One star One star	28/07/2023	Loved the Dr.
One star One star One star One star One star	09/07/2023	Dr. Arellano is very kind and knowledgeable .
One star One star One star One star One star	29/06/2023	Dr. Arellano has been amazing this whole journey. She and her team are absolute professionals and rockstars.
One star One star One star One star One star	18/05/2023	Excited for the possibility of participating in a clinical trial the provider said was coming soon.
One star One star One star One star One star	11/05/2023	They take the time with one to answer questions.
One star One star One star One star One star	27/04/2023	Dr. Arellano provided a detailed explanation of my disease state and treatment possibilities. I have never had a physician take time to be certain I had a through understanding of my medical condition.She is an excellent practitioner!
One star One star One star One star One star	20/04/2023	Dr. Arellano has always provided excellent care.
One star One star One star One star One star	30/03/2023	All ways check on overall condition
One star One star One star One star One half star	23/02/2023	I highly recommend dr Martha, very thorough
One star One star One star One star One star	10/01/2023	Dr Martha Arellano is the BEST! A GREAT Ambassador for Emory's Winship Cancer Institute!
One star One star One star One star One star	01/12/2022	Dr. Arellano is excellent. She listens and truly considers all aspects of care. I would highly recommend her.
One star One star One star One star One star	27/10/2022	Excellent conversation
One star One star One star One star One star	13/09/2022	Good
One star One star One star One star One star	13/09/2022	She is all I or any one could ever need,
One star One star One star One star One star	14/07/2022	Very pleased
One star One star One star One star One star	23/06/2022	Excellent physician!
One star One star One star One star One star	13/06/2022	All good
One star One star One star One star One star	07/06/2022	She is without doubt one of the most outstanding, professional and caring doctors I have even had. She really cares for me and my situation.